To me it stands to reason that BLT that US "payers" would be...

To me it stands to reason that BLT that US "payers" would be prepared to pay up if TT-034 proved to be more efficacious and cost-effective than the available alternatives, whatever their mode(s) of delivery. Here in Australia the Therapeutic Goods Administration would evaluate the scientific evidence and advise whether TT-034 (or a successor) is safe for clinical use. Then it would be up to the manufacturer and various lobby groups to convince the Australian feds that TT-034 (or a successor) should be made available through the Prescriber Benefits Scheme, or else be made available via one or other of the subsidised prescribing mechanisms that are available in this country.